Hematopoietic Stem Cell Transplantation Market by Transplant Type, Indication, Application & Region | Forecast 2023 to 2033

<p>The global <strong>hematopoietic stem cell transplantation market </strong>garnered a market value of US$ 7 Billion in 2023 and is expected to accumulate a market value of US$ 15 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Because of the rising frequency of leukemia and lymphoma, the worldwide hematopoietic stem cell transplantation industry is predicted to rise significantly over the forecast period.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Key Statistics</td></tr><tr><th scope='row'>Expected Market Value (2023)</th><td>US$ 7 Billion</td></tr><tr><th scope='row'>Anticipated Forecast Value (2033)</th><td>US$ 15 Billion</td></tr><tr><th scope='row'>Projected Growth Rate (2023 to 2033)</th><td>8% CAGR</td></tr></tbody></table><p>Report Scope</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Market Value in 2023</th><td>US$ 7 Billion</td></tr><tr><th scope='row'>Market Value in 2033</th><td>US$ 15 Billion</td></tr><tr><th scope='row'>Growth Rate</th><td>CAGR of 8% from 2023 to 2032</td></tr><tr><th scope='row'>Base Year for Estimation</th><td>2021</td></tr><tr><th scope='row'>Historical Data</th><td>2018 to 2022</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Quantitative Units</th><td>Revenue in US Billion and CAGR from 2023 to 2032</td></tr><tr><th scope='row'>Report Coverage</th><td>Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis</td></tr><tr><th scope='row'>Segments Covered</th><td><ul><li>Transplant Type</li><li>Indication</li><li>Application</li><li>Region</li></ul></td></tr><tr><th scope='row'>Regions Covered</th><td><ul><li>North America</li><li>Latin America</li><li>Europe</li><li>Asia Pacific</li><li>Middle East &amp; Africa (MEA)</li></ul></td></tr><tr><th scope='row'>Key Countries Profiled</th><td><ul><li>USA</li><li>Canada</li><li>Brazil</li><li>Mexico</li><li>Germany</li><li>UK</li><li>France</li><li>Spain</li><li>Italy</li><li>China</li><li>Japan</li><li>South Korea</li><li>India</li><li>Malaysia</li><li>Singapore</li><li>Australia</li><li>New Zealand</li><li>GCC</li><li>South Africa</li><li>Israel</li></ul></td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Pluristem Therapeutics Inc.</li><li>CellGenix GmbH</li><li>Regen Biopharma Inc.</li><li>Lonza Group</li><li>Sanofi</li><li>Taiga Biotechnologies, Inc.</li><li>Takeda Pharmaceutical Company Limited</li><li>Escape Therapeutics, Inc.</li><li>Bluebird Bio</li><li>Talaris Therapeutics</li></ul></td></tr><tr><th scope='row'>Customization</th><td>Available Upon Request</td></tr></tbody></table>

<p>全球造血干细胞移植市场在2023年实现了70亿美元的市值，并预计在2023年至2033年的预测期间，通过实现8%的复合年增长率（CAGR），累积达到150亿美元的市值。鉴于白血病和淋巴瘤发病率的上升，全球造血干细胞移植行业预计在预测期间将显著增长。</p><table><tbody><tr><th scope='row'>数据点</th><td>关键统计数据</td></tr><tr><th scope='row'>预期市场价值（2023年）</th><td>70亿美元</td></tr><tr><th scope='row'>预期预测价值（2033年）</th><td>150亿美元</td></tr><tr><th scope='row'>预测增长率（2023年至2033年）</th><td>8% CAGR</td></tr></tbody></table><p>报告范围</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>2023年市场价值</th><td>70亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>150亿美元</td></tr><tr><th scope='row'>增长率</th><td>2023年至2032年的8%复合年增长率</td></tr><tr><th scope='row'>估算基准年</th><td>2021年</td></tr><tr><th scope='row'>历史数据</th><td>2018年至2022年</td></tr><tr><th scope='row'>预测期</th><td>2023年至2033年</td></tr><tr><th scope='row'>定量单位</th><td>以亿美元为单位的收入和2023年至2032年的复合年增长率</td></tr><tr><th scope='row'>报告覆盖范围</th><td>收入预测、公司排名、竞争格局、增长因素、趋势和定价分析</td></tr><tr><th scope='row'>覆盖细分市场</th><td><ul><li>移植类型</li><li>适应症</li><li>应用</li><li>地区</li></ul></td></tr><tr><th scope='row'>覆盖地区</th><td><ul><li>北美</li><li>拉丁美洲</li><li>欧洲</li><li>亚太地区</li><li>中东及非洲（MEA）</li></ul></td></tr><tr><th scope='row'>概述的关键国家</th><td><ul><li>美国</li><li>加拿大</li><li>巴西</li><li>墨西哥</li><li>德国</li><li>英国</li><li>法国</li><li>西班牙</li><li>意大利</li><li>中国</li><li>日本</li><li>韩国</li><li>印度</li><li>马来西亚</li><li>新加坡</li><li>澳大利亚</li><li>新西兰</li><li>GCC</li><li>南非</li><li>以色列</li></ul></td></tr><tr><th scope='row'>概述的关键公司</th><td><ul><li>Pluristem Therapeutics Inc.</li><li>CellGenix GmbH</li><li>Regen Biopharma Inc.</li><li>Lonza Group</li><li>Sanofi</li><li>Taiga Biotechnologies, Inc.</li><li>Takeda Pharmaceutical Company Limited</li><li>Escape Therapeutics, Inc.</li><li>Bluebird Bio</li><li>Talaris Therapeutics</li></ul></td></tr><tr><th scope='row'>定制</th><td>根据需求提供</td></tr></tbody></table>